TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells

Prostate

Volumn 75, Issue 10, 2015, Pages 1020-1033

  Jain, Sumeet ^a,b   Suklabaidya, Sujit ^a,b   Das, Biswajit ^a   Raghav, Sunil K ^a   Batra, Surinder K ^c   Senapati, Shantibhusan ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b MANIPAL UNIVERSITY   (India)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

autophagy; CCL2; infection; lipopolysaccharide; LPS; metabolic stress; prostate cancer; TLR4

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 4; CULTURE MEDIUM; LIPOPOLYSACCHARIDE; MESSENGER RNA; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TLR4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; CANCER CELL; CARCINOGENESIS; CELL AGING; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROAUTOPHAGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOPHAGY; CANCER TRANSPLANTATION; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; ESCHERICHIA COLI; EXPERIMENTAL NEOPLASM; GENETICS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELL AGING; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINE CCL2; CULTURE MEDIA, SERUM-FREE; ESCHERICHIA COLI; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPOLYSACCHARIDES; MALE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; RATS; RNA, MESSENGER; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTOR 4;

EID: 84929024875     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22983     Document Type: Article

References (47)

1. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG,. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7 (4): 256-269.
2. Elkahwaji JE, Hauke RJ, Brawner CM,. Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. Br J Cancer 2009; 101 (10): 1740-1748.
3. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG,. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005; 26 (7): 1170-1181.
4. Elkahwaji JE,. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol 2012; 5: 1-10.
5. Satyanarayana R, Parekh D,. Prevention and treatment of biopsy-related complications. Curr Urol Rep 2014; 15 (2): 381.
6. Ehdaie B, Vertosick E, Spaliviero M, Giallo-Uvino A, Taur Y, O'Sullivan M, Livingston J, Sogani P, Eastham J, Scardino P, Touijer K,. The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 2014; 191 (3): 660-664.
7. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schroder FH, Roobol MJ,. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61 (6): 1110-1114.
8. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA,. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 2008; 10 (6): 1235-1248.
9. Jones RG, Thompson CB,. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23 (5): 537-548.
10. Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, Barokas A, Kwok B, Bowden M, Smith S, Wu X, Korshunov A, Hielscher T, Northcott PA, Galpin JD, Ahern CA, Wang Y, McCabe MG, Collins VP, Jones RG, Pollak M, Delattre O, Gleave ME, Jan E, Pfister SM, Proud CG, Derry WB, Taylor MD, Sorensen PH,. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013; 153 (5): 1064-1079.
11. Zhang Y, Wang Y, Yuan J, Qin W, Liu F, Wang F, Zhang G, Yang X,. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells. Cell Biol Toxicol 2012; 28 (4): 269-277.
12. Pei Z, Li H, Guo Y, Jin Y, Lin D,. Sodium selenite inhibits the expression of VEGF, TGFbeta(1) and IL-6 induced by LPS in human PC3 cells via TLR4-NF-(K)B signaling blockage. Int Immunopharmacol 2010; 10 (1): 50-56.
13. Pei Z, Lin D, Song X, Li H, Yao H,. TLR4 signaling promotes the expression of VEGF and TGFbeta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cell Immunol 2008; 254 (1): 20-27.
14. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, Liu DX,. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 2009; 46 (15): 2876-2884.
15. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H,. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65 (12): 5009-5014.
16. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G,. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66 (7): 3859-3868.
17. Tang XY, Zhu YQ, Wei B, Wang H,. Expression and functional research of TLR4 in human colon carcinoma. Am J Med Sci 2010; 339 (4): 319-326.
18. Yang H, Wang B, Wang T, Xu L, He C, Wen H, Yan J, Su H, Zhu X,. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS ONE 2014; 9 (10): e109980.
19. Chow SC, Gowing SD, Cools-Lartigue JJ, Chen CB, Berube J, Yoon HW, Chan CH, Rousseau MC, Bourdeau F, Giannias B, Roussel L, Qureshi ST, Rousseau S, Ferri LE,. Gram negative bacteria increase non-small cell lung cancer metastasis via toll-like receptor 4 activation and mitogen-activated protein kinase phosphorylation. Int J Cancer 2014.
20. Thomas R, Kim MH,. HIF-1 alpha: A key survival factor for serum-deprived prostate cancer cells. Prostate 2008; 68 (13): 1405-1415.
21. Tang DG, Li L, Chopra DP, Porter AT,. Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 1998; 58 (15): 3466-3479.
22. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS,. The essence of senescence. Genes Dev 2010; 24 (22): 2463-2479.
23. Roca H, Varsos Z, Pienta KJ,. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 2008; 283 (36): 25057-25073.
24. Roca H, Varsos ZS, Pienta KJ,. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia 2009; 11 (12): 1309-1317.
25. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ,. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006; 8 (7): 578-586.
26. Guijarro-Munoz I, Compte M, Alvarez-Cienfuegos A, Alvarez-Vallina L, Sanz L,. Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-kappaB signaling pathway and proinflammatory response in human pericytes. J Biol Chem 2014; 289 (4): 2457-2468.
27. Low-Marchelli JM, Ardi VC, Vizcarra EA, van Rooijen N, Quigley JP, Yang J,. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res 2013; 73 (2): 662-671.
28. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM,. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012; 2012: 948098.
29. Oblak A, Jerala R,. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011; 2011: 609579.
30. Kundu SD, Lee C, Billips BK, Habermacher GM, Zhang Q, Liu V, Wong LY, Klumpp DJ, Thumbikat P,. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 2008; 68 (2): 223-229.
31. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV,. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002; 115 (Pt 1): 141-151.
32. Li Z, Zhang H, Chen Y, Fan L, Fang J,. Forkhead transcription factor FOXO3a protein activates nuclear factor kappaB through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation. J Biol Chem 2012; 287 (21): 17737-17745.
33. Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, Rescigno M,. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 2010; 29 (13): 2242-2252.
34. Su M, Mei Y, Sinha S,. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol 2013; 2013: 102735.
35. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, Tsujimoto Y,. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004; 6 (12): 1221-1228.
36. Roebuck KA, Carpenter LR, Lakshminarayanan V, Page SM, Moy JN, Thomas LL,. Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB. J Leukoc Biol 1999; 65 (3): 291-298.
37. Zhang ZJ, Zhao LX, Cao DL, Zhang X, Gao YJ, Xia C,. Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells. Cell Mol Neurobiol 2012; 32 (6): 1003-1010.
38. Mathew R, Karantza-Wadsworth V, White E,. Assessing metabolic stress and autophagy status in epithelial tumors. Methods Enzymol 2009; 453: 53-81.
39. Marino G, Salvador-Montoliu N, Fueyo A, Knecht E, Mizushima N, Lopez-Otin C,. Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. J Biol Chem 2007; 282 (25): 18573-18583.
40. Rezania S, Amirmozaffari N, Rashidi N, Mirzadegan E, Zarei S, Ghasemi J, Zarei O, Katouzian L, Zarnani AH,. The same and not the same: Heterogeneous functional activation of prostate tumor cells by TLR ligation. Cancer Cell Int 2014; 14: 54.
41. Matthews E, Yang T, Janulis L, Goodwin S, Kundu SD, Karpus WJ, Lee C,. Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells. Br J Cancer 2000; 83 (4): 519-525.
42. Gong D, Shi W, Yi SJ, Chen H, Groffen J, Heisterkamp N,. TGFbeta signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol 2012; 13: 31.
43. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS,. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14 (2): 207-215.
44. Kwon OJ, Zhang L, Ittmann MM, Xin L,. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A 2013.
45. Poutahidis T, Cappelle K, Levkovich T, Lee CW, Doulberis M, Ge Z, Fox JG, Horwitz BH, Erdman SE,. Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. PLoS ONE 2013; 8 (8): e73933.
46. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE,. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 1998; 18 (5): 2845-2854.
47. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS,. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109 (8): 2784-2789.